Fresenius Kabi up as SAT sets aside SEBI's delisting order

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Shares of Fresenius Kabi Oncology spiked 10.8 percent intraday after the Securities Appellate Tribunal (SAT) set aside SEBI's order in the company's delisting case.

SAT says that the company does not require to comply with SEBI's conditions. Fresenius Kabi had moved SAT against SEBI's conditional nod for delisting.

Last week the government approved Rs 349 crore FDI proposal of the company. This foreign direct investment (FDI) approval would allow parent company to acquire shares of the Indian subsidiary which will then be delisted.

Parent company Fresenius Kabi (Singapore) Private Limited holds 81 percent stake in the company as of June 2013.

As per the SEBI order dated July 22, the company has to complete the delisting process within three months from the date of the order after meeting some conditions.

At 14:00 hours IST, the stock was up 2.65 percent at Rs 127.85 amid large volumes on the Bombay Stock Exchange.

Trading volumes increased 11 percent to 2,17,298 equity shares as compared to its five-day average of 19,841 shares.